Deerfield group reports 4.34% CalciMedica (CALC) stake via warrants
Rhea-AI Filing Summary
CalciMedica Inc. (CALC) received an amended Schedule 13G from investment entities affiliated with Deerfield and James E. Flynn. The filing reports beneficial ownership of 653,253 shares of common stock, all issuable upon exercise of warrants held by Deerfield Partners, L.P.
The position represents 4.34% of CalciMedica’s common stock. All reporting persons disclose zero sole voting or dispositive power and shared voting and dispositive power over the same 653,253 shares. They also certify the holdings were not acquired to change or influence control of CalciMedica, characterizing the stake as passive.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in CalciMedica (CALC) does Deerfield report?
Deerfield-affiliated entities and James E. Flynn report beneficial ownership of 653,253 CalciMedica common shares, all issuable upon exercise of warrants. This position represents 4.34% of the company’s common stock, according to the amended Schedule 13G filing.
Is Deerfield’s CalciMedica (CALC) position classified as passive or activist?
The reporting persons certify the securities were not acquired and are not held to change or influence control of CalciMedica. This language indicates a passive investment intent under the Schedule 13G framework, rather than an activist control-oriented position.
Why does the CalciMedica (CALC) Schedule 13G/A mention ownership of 5 percent or less?
Item 5 indicates ownership of 5 percent or less of CalciMedica’s common stock. The reported 4.34% stake reflects a sub‑5% holding, which still requires reporting but is below the typical 5% threshold often associated with larger significant holders.